GraniteShares YieldBoost AMZN ETF (AZYY)

On our desk, looking at AZYY's mechanism of selling put options on the 2x Long AMZN Daily ETF, we see massive structural leverage risks. The fund's beta sits at 1.14 while logging a steep 35.94% maximum drawdown. Because it relies heavily on weekly options strategies tied to daily double-long underlying ETFs, it is completely unsuited for any long-term portfolio configuration.

From a risk management standpoint, AZYY fails basic viability tests. With assets under management lingering around $2.4 million to $3.18 million, it sits far below the $50 million institutional viability threshold and faces immediate closure risk. The one-year Sortino ratio of -1.41 further confirms that the fund's downside volatility vastly outweighs any derivative income generated.

Running quantitative checks on AZYY's execution efficiency shows a major red flag: a microscopic daily trading volume of roughly $37.4K paired with an exorbitant median bid-ask spread of 11.40%. Combined with a 1.07% expense ratio, the trading frictions alone cannibalize whatever high nominal distribution yield the fund is trying to pay out.

Even though our team typically tracks life sciences, analyzing financial vehicles like AZYY reveals fascinating structural designs. The synthetic active management structure targets double-long Amazon exposure via weekly income distributions, but the high return-of-capital distribution profile shows that much of the cash being paid out is simply returning the investor's own principal.

Reviewing public disclosures and trading metrics for AZYY on platforms like TradingView and Barchart, the fund exhibits an annualized dividend yield surpassing 34% to 55%. However, this high headline yield is entirely offset by the steep -34.71% all-time NAV depreciation and the severe execution costs embedded in its thin liquidity profile.